{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:40Z","timestamp":1786119460730,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/aog.0b013e3181deba40","type":"journal-article","created":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T03:29:39Z","timestamp":1274239779000},"page":"1256-1262","source":"Crossref","is-referenced-by-count":161,"title":["Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss"],"prefix":"10.1097","volume":"115","author":[{"given":"Panayiotis D.","family":"Ziakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthaios","family":"Pavlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Voulgarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210728","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.thromres.2004.08.006","article-title":"Treatment of antiphospholipid syndrome in pregnancy\u2013a systematic review of randomized therapeutic trials.","volume":"114","author":"Lassere","year":"2004","journal-title":"Thromb Res"},{"key":"R2-23-20210728","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1191\/0961203303lu393oa","article-title":"Treatment of pregnant patients with antiphospholipid syndrome.","volume":"12","author":"Tincani","year":"2003","journal-title":"Lupus"},{"key":"R3-23-20210728","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/oxfordjournals.humrep.a135907","article-title":"High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.","volume":"10","author":"Rai","year":"1995","journal-title":"Hum Reprod"},{"key":"R4-23-20210728","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0015-0282(97)81475-6","article-title":"Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody.","volume":"68","author":"Takakuwa","year":"1997","journal-title":"Fertil Steril"},{"key":"R5-23-20210728","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM199707173370303","article-title":"Pregnancy loss in the antiphospholipid-antibody syndrome\u2013a possible thrombogenic mechanism.","volume":"337","author":"Rand","year":"1997","journal-title":"N Engl J Med"},{"key":"R6-23-20210728","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0049-3848(89)90460-X","article-title":"Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion.","volume":"55","author":"Woodhams","year":"1989","journal-title":"Thromb Res"},{"key":"R7-23-20210728","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(05)60080-3","article-title":"Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death.","volume":"352","author":"Chamley","year":"1998","journal-title":"Lancet"},{"key":"R8-23-20210728","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"R9-23-20210728","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"R10-23-20210728","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(00)04239-2","article-title":"Systemic lupus erythematosus.","volume":"357","author":"Ruiz-Irastorza","year":"2001","journal-title":"Lancet"},{"issue":"6 suppl","key":"R11-23-20210728","doi-asserted-by":"crossref","first-page":"844S","DOI":"10.1378\/chest.08-0761","article-title":"Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Bates","year":"2008","journal-title":"Chest"},{"key":"R12-23-20210728","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R13-23-20210728","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.080763","article-title":"Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.","volume":"36","author":"Laskin","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"R14-23-20210728","first-page":"CD002859","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.","author":"Empson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-23-20210728","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"key":"R16-23-20210728","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00129784-200808010-00003","article-title":"Low-molecular-weight heparins: mechanisms, trials, and role in contemporary interventional medicine.","volume":"8","author":"Canales","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"R17-23-20210728","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MCP.0b013e32832f5d9d","article-title":"Low-molecular-weight heparin for thromboprophylaxis.","volume":"15","author":"Camporese","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"R18-23-20210728","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11239-007-0170-1","article-title":"Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.","volume":"26","author":"Happe","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"R19-23-20210728","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R20-23-20210728","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R21-23-20210728","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","article-title":"Estimation of a common effect parameter from sparse follow-up data.","volume":"41","author":"Greenland","year":"1985","journal-title":"Biometrics"},{"key":"R22-23-20210728","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R23-23-20210728","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.fertnstert.2004.11.002","article-title":"Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.","volume":"83","author":"Noble","year":"2005","journal-title":"Fertil Steril"},{"key":"R24-23-20210728","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1701-2163(16)30644-2","article-title":"Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.","volume":"26","author":"Stephenson","year":"2004","journal-title":"J Obstet Gynaecol Can"},{"key":"R25-23-20210728","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/humrep\/17.11.2981","article-title":"Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population.","volume":"17","author":"Franklin","year":"2002","journal-title":"Hum Reprod"},{"key":"R26-23-20210728","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R27-23-20210728","first-page":"CR132","article-title":"The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies.","volume":"12","author":"Goel","year":"2006","journal-title":"Med Sci Monit"},{"key":"R28-23-20210728","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kep373","article-title":"Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.","volume":"49","author":"Mak","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R29-23-20210728","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-0897.1996.tb00501.x","article-title":"A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin.","volume":"35","author":"Kutteh","year":"1996","journal-title":"Am J Reprod Immunol"},{"key":"R30-23-20210728","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ajog.2004.05.014","article-title":"Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro.","volume":"191","author":"Bose","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R31-23-20210728","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(81)92087-0","article-title":"Arterial thrombosis, intrauterine death and \u201clupus\u201d antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation.","volume":"1","author":"Carreras","year":"1981","journal-title":"Lancet"},{"key":"R32-23-20210728","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajog.2004.09.029","article-title":"Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.","volume":"192","author":"Bose","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R33-23-20210728","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1196\/annals.1422.054","article-title":"Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature.","volume":"1108","author":"Di Simone","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R34-23-20210728","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0002-9378(98)70277-7","article-title":"Placental pathology in systemic lupus erythematosus: a prospective study.","volume":"179","author":"Magid","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"R35-23-20210728","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1191\/0961203303lu397oa","article-title":"Activation of complement mediates antiphospholipid antibody-induced pregnancy loss.","volume":"12","author":"Salmon","year":"2003","journal-title":"Lupus"},{"key":"R36-23-20210728","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"R37-23-20210728","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-0897.2007.00500.x","article-title":"Antiphospholipid antibodies: effects on trophoblast and endothelial cells.","volume":"58","author":"D'Ippolito","year":"2007","journal-title":"Am J Reprod Immunol"},{"key":"R38-23-20210728","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1095\/biolreprod56.1.50","article-title":"Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion.","volume":"56","author":"Katsuragawa","year":"1997","journal-title":"Biol Reprod"},{"key":"R39-23-20210728","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2004.021444","article-title":"Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro.","volume":"64","author":"Di Simone","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R40-23-20210728","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/humrep\/17.4.1067","article-title":"Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure.","volume":"17","author":"Sebire","year":"2002","journal-title":"Hum Reprod"},{"key":"R41-23-20210728","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0897.1995.tb01133.x","article-title":"Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL).","volume":"33","author":"Ermel","year":"1995","journal-title":"Am J Reprod Immunol"},{"key":"R42-23-20210728","first-page":"455","article-title":"Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.","volume":"101","author":"Franklin","year":"2003","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201006000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:21:16Z","timestamp":1786040476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201006000-00023"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e3181deba40","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}